Fasken

Cycle Momentum is a Montreal-based accelerator established in 2014 that focuses on supporting cleantech startups. It is dedicated to working with entrepreneurs who develop and commercialize innovative clean technologies, aiming to cultivate globally competitive companies. The accelerator provides a tailored program that includes training workshops, networking opportunities, and access to experienced mentors. Additionally, Cycle Momentum connects these startups with investors to enhance their growth potential. By concentrating on seed-stage, early-stage, and later-stage companies, particularly in B2B, commercial transportation, energy, and cleantech sectors, Cycle Momentum plays a crucial role in fostering the development of promising Canadian ventures in the clean technology arena.

Pro Bono Ontario (PBO) bridges the gap between lawyers who want to donate their services and low-income Ontarians who cannot afford a lawyer or qualify for legal aid.

Asmacure Ltée is a clinical-stage biopharmaceutical company based in Quebec City, Canada, founded in 2002 by Dr. Yvon Cormier and Dr. Evelyne Israel-Assayag. The company specializes in the development of proprietary molecules that target cholinergic receptors to address inflammation, particularly in pulmonary airway diseases such as moderate asthma and chronic obstructive pulmonary disease (COPD). Its lead compound, ASM-024, features a multi-functional mechanism of action with both nicotinic and muscarinic effects, demonstrating anti-inflammatory properties, bronchoprotection, and smooth muscle relaxation in pre-clinical studies. ASM-024 has shown clinical proof of concept in a phase 2 trial, where it was administered as a solution for nebulization, yielding significant improvements in lung function metrics. Asmacure is currently advancing ASM-024 into clinical use with a dry powder for inhalation formulation, which is expected to enhance lung deposition and optimize dosing for patients. The company operates as a subsidiary of Odan Laboratories Ltd.